OSMR Regulation of Glioblastoma Pathogenesis

OSMR 对胶质母细胞瘤发病机制的调节

• 批准号: 389933
• 负责人: Jahani-Asl Arezu
• 金额: $ 54.89万
• 依托单位: CIUSSS de Centre-Ouest-de-l'Ile-de-Montral-Jewish General
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2018
• 资助国家: 加拿大
• 起止时间: 2018-09-01 至 2023-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=389933&lang=en
• 关键词: Brain; Egfrviii; Genetics; Glioblastoma; Neuroscience; Osmr; Phosphorylation; Rna-Seq; Stat3; Transcription

Glioblastoma is the most aggressive primary brain tumor in adult with a median survival rate of only 16 months after the disease diagnosis. The present standard of care includes maximal surgical removal of the tumors followed by standard treatment with ra

胶质母细胞瘤是成人中最具侵袭性的原发性脑肿瘤，在疾病诊断后中位生存率仅为16个月。目前的标准治疗包括最大限度地手术切除肿瘤，然后用RA进行标准治疗。